MedTrace Logo

Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients

NCT01789619 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2015-05-29

No results posted yet for this study

Summary

To evaluate the clinical efficacy of the extended release formulation of tacrolimus (Advagraf®) in patients with severe atopic dermatitis, who can not be treated adequately with cyclosporine A because of side effects and/or non-responsiveness.

Conditions

Interventions

DRUG

Extended release tacrolimus (Advagraf®)

Sponsors & Collaborators

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • C AFM Bruijnzeel-Koomen, MD, PhD · UMC Utrecht

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01789619 on ClinicalTrials.gov